In a circular dated January 7, addressed to the chief executive officers (CEOs) of the general and health insurance companies, the regulator has said, “ … insurers are advised to review the claims denied/ deductions made in such claims and take appropriate action for ensuring that the claims are settled as per terms and conditions”.
The insurance regulator said that it has come across instances wherein claims were denied or there was deduction on expenses incurred towards “antibody cocktail therapy” treatment for Covid-19, under the pretext that it is an experimental treatment.
“However, it may please be noted that the antibody Cocktail (Casirivimab and Imdevimab) has been given emergency use authorisation (EUA) in May, 2021, by Central Drugs Standard Control Organisation (CDSO) in our country”, the insurance regulator said in the circular directed to the CEOs of insurance companies.
Antibody cocktail is a combination of two types of genetically engineered antibodies. They are similar to the antibodies produced in a human body but different because they are made in a lab. The antibody cocktail is to be administered for the treatment of mild to moderate coronavirus disease in adults and paediatric patients (12 years of age or older, weighing at least 40 kg) who are confirmed to be infected with SARS-COV2 and who are at high risk of developing severe Covid-19 disease and do not require oxygen at that stage.
Swiss major Roche had got approval for its antibody cocktail comprising two antibodies: casirivimab and imdevimab. Cipla had launched the medicine here at the price of Rs 59,750 per patient.
The insurance regulator has asked the insurance companies to put in place an effective claim settlement procedure to update the developments/ approvals given by relevant authorities so that all claims are settled as per terms and conditions.
To read the full story, Subscribe Now at just Rs 249 a month
Already a subscriber? Log in
Subscribe To BS Premium
₹249
Renews automatically
₹1699₹1999
Opt for auto renewal and save Rs. 300 Renews automatically
₹1999
What you get on BS Premium?
-
Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
-
Pick your favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
Need More Information - write to us at assist@bsmail.in